Annual CFF
$95.69 M
+$92.75 M+3143.90%
31 December 2023
Summary:
Allogene Therapeutics annual cash flow from financing activities is currently $95.69 million, with the most recent change of +$92.75 million (+3143.90%) on 31 December 2023. During the last 3 years, it has fallen by -$537.90 million (-84.90%). ALLO annual CFF is now -87.59% below its all-time high of $771.18 million, reached on 31 December 2018.ALLO Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$679.00 K
-$107.92 M-99.37%
30 September 2024
Summary:
Allogene Therapeutics quarterly cash flow from financing activities is currently $679.00 thousand, with the most recent change of -$107.92 million (-99.37%) on 30 September 2024. Over the past year, it has dropped by -$3.61 million (-84.15%). ALLO quarterly CFF is now -99.89% below its all-time high of $600.17 million, reached on 30 June 2020.ALLO Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$111.09 M
-$3.61 M-3.14%
30 September 2024
Summary:
Allogene Therapeutics TTM cash flow from financing activities is currently $111.09 million, with the most recent change of -$3.61 million (-3.14%) on 30 September 2024. Over the past year, it has increased by +$15.50 million (+16.22%). ALLO TTM CFF is now -85.61% below its all-time high of $771.87 million, reached on 31 March 2019.ALLO TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALLO Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +3143.9% | -84.2% | +16.2% |
| 3 y3 years | -84.9% | -71.5% | +351.2% |
| 5 y5 years | -87.6% | -56.6% | -68.0% |
ALLO Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -84.9% | +3143.9% | -99.4% | +2729.2% | -3.1% | +3774.7% |
| 5 y | 5 years | -87.6% | +3143.9% | -99.9% | +2729.2% | -83.6% | +3774.7% |
| alltime | all time | -87.6% | +3143.9% | -99.9% | -85.6% |
Allogene Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $679.00 K(-99.4%) | $111.09 M(-3.1%) |
| June 2024 | - | $108.60 M(+6482.0%) | $114.69 M(+20.0%) |
| Mar 2024 | - | $1.65 M(+964.5%) | $95.61 M(-0.1%) |
| Dec 2023 | $95.69 M(+3143.9%) | $155.00 K(-96.4%) | $95.69 M(+0.1%) |
| Sept 2023 | - | $4.29 M(-95.2%) | $95.59 M(+3.5%) |
| June 2023 | - | $89.52 M(+5071.8%) | $92.37 M(+3121.7%) |
| Mar 2023 | - | $1.73 M(+3663.0%) | $2.87 M(-2.8%) |
| Dec 2022 | $2.95 M(-75.3%) | $46.00 K(-95.7%) | $2.95 M(-8.6%) |
| Sept 2022 | - | $1.07 M(+4341.7%) | $3.23 M(-29.0%) |
| June 2022 | - | $24.00 K(-98.7%) | $4.54 M(-41.3%) |
| Mar 2022 | - | $1.81 M(+463.4%) | $7.73 M(-35.4%) |
| Dec 2021 | $11.96 M | $322.00 K(-86.5%) | $11.96 M(-51.4%) |
| Sept 2021 | - | $2.38 M(-25.9%) | $24.62 M(-5.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2021 | - | $3.21 M(-46.8%) | $26.09 M(-95.8%) |
| Mar 2021 | - | $6.04 M(-53.4%) | $623.05 M(-1.7%) |
| Dec 2020 | $633.59 M(+974.6%) | $12.98 M(+236.9%) | $633.59 M(-6.4%) |
| Sept 2020 | - | $3.85 M(-99.4%) | $677.09 M(+0.3%) |
| June 2020 | - | $600.17 M(+3518.6%) | $674.80 M(+801.4%) |
| Mar 2020 | - | $16.59 M(-70.6%) | $74.86 M(+27.0%) |
| Dec 2019 | $58.96 M(-92.4%) | $56.47 M(+3506.3%) | $58.96 M(-83.0%) |
| Sept 2019 | - | $1.57 M(+563.6%) | $347.01 M(-44.0%) |
| June 2019 | - | $236.00 K(-65.5%) | $619.50 M(-19.7%) |
| Mar 2019 | - | $684.00 K(-99.8%) | $771.87 M(+0.1%) |
| Dec 2018 | $771.18 M | $344.52 M(+25.7%) | $771.18 M(+80.7%) |
| Sept 2018 | - | $274.06 M(+79.6%) | $426.66 M(+179.6%) |
| June 2018 | - | $152.60 M(>+9900.0%) | $152.60 M(>+9900.0%) |
| Mar 2018 | - | $0.00 | $0.00 |
FAQ
- What is Allogene Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Allogene Therapeutics?
- What is Allogene Therapeutics annual CFF year-on-year change?
- What is Allogene Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Allogene Therapeutics?
- What is Allogene Therapeutics quarterly CFF year-on-year change?
- What is Allogene Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Allogene Therapeutics?
- What is Allogene Therapeutics TTM CFF year-on-year change?
What is Allogene Therapeutics annual cash flow from financing activities?
The current annual CFF of ALLO is $95.69 M
What is the all time high annual CFF for Allogene Therapeutics?
Allogene Therapeutics all-time high annual cash flow from financing activities is $771.18 M
What is Allogene Therapeutics annual CFF year-on-year change?
Over the past year, ALLO annual cash flow from financing activities has changed by +$92.75 M (+3143.90%)
What is Allogene Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of ALLO is $679.00 K
What is the all time high quarterly CFF for Allogene Therapeutics?
Allogene Therapeutics all-time high quarterly cash flow from financing activities is $600.17 M
What is Allogene Therapeutics quarterly CFF year-on-year change?
Over the past year, ALLO quarterly cash flow from financing activities has changed by -$3.61 M (-84.15%)
What is Allogene Therapeutics TTM cash flow from financing activities?
The current TTM CFF of ALLO is $111.09 M
What is the all time high TTM CFF for Allogene Therapeutics?
Allogene Therapeutics all-time high TTM cash flow from financing activities is $771.87 M
What is Allogene Therapeutics TTM CFF year-on-year change?
Over the past year, ALLO TTM cash flow from financing activities has changed by +$15.50 M (+16.22%)